PolarityTE Inc.

PolarityTE — Investor Presentation (October 2018)

55 slides from PolarityTE's investor presentation, Oct 1, 2018

  1. Slide 1: PolarityTE: Self Regenerates Self

    the i Regenerates Sef”

  2. Slide 2: Forward-Looking Statements

    FORWARDLOOKING STATEMENTS This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warrant as to the completeness of this information or, in the case of projections, as to their attainability or the accuracy and completeness of

  3. Slide 3: PolarityTE commercial-stage biotechnology and tissue regenerative company

    delaritylE Minerese|inedemerctés Sell’ commercial-stage biotechnology and tissue NEO- generative company focused on transforming the lives of patients by delivering a range of functional therapies using our novel platform technology

  4. Slide 4: Ask yourself: name one company or product that truly regenerates anything

    Le Ask yourself —Name one company or product that = truly regenerates ANYTHING? i ee? ale = Se ae wee - Lg > 4 SS =

  5. Slide 5: We Are Often Asked Why We Left Medicine

    We Are Often Asked Why We Left Medicine

  6. Slide 6: The WHY: We Could Do More

    The WHY || We Could Do More The Washington Post US experts to help treat burn patients from Taiwan dust explosion | we. wi President Ma brings expert medical to offer advice on burns treatment “7

  7. Slide 7: Science Forgets: Basic Things Matter and Simple Things Work

    Science Forgets: Basic Things Matter and Simple Things Work

  8. Slide 8: Complex Simplicity is Reality

    Complex Simplicity is Reality

  9. Slide 9: PolarityTE: We Design Platform Technologies

    PolarityTE® - We Design Platform Technologies We believe precise design and development of our Core TE Tissue Systems, utilizing novel Minimally Polarized Functional Units (MPFUs), permits us to regenerate a full spectrum of functionally-polarized complex tissues AUTOLOGOUS- FROM THE PATIENT FOR THE

  10. Slide 10: Pipeline Technologies, Platforms & Product Systems

    PolarityTE® || Pipeline Technologies, Platforms & Product Systems Core “TE” Tissue Platform Technologies Program Platform(s) Optimization & Development Prototype Modeling Clinical Development Market Commercialization Cutaneous &Integument Skin TE i > Osseous MSK OsteoTE = [ Chondral MSK CartTE [ > S

  11. Slide 11: Starting with SKIN

    Starting with SKIN

  12. Slide 12: Tissue is NOT Simply Engineered - It Engineers Itself

    Tissue is NOT Simply Engineered - It Engineers Itself | Comparing Skin Substitutes to Actual Skin Current Commercial Skin Substitutes /Dermal (Composite)

  13. Slide 13: Understanding the Fundamentals of REAL Skin

    Understanding the Fundamentals of REAL Skin Skin is MUCH More than Keratinocytes Compartment Cells Appendages & Function/Responses Structures H H Keratinocyte (predominant) Rete Pes Protective barrier Epidermis Melanocyte * Pigmentation UV protection Immunity (antigen presentation) Langerhanscell Co

  14. Slide 14: The Problem with Regenerative Medicine is Tissue Engineering

    The Problem with Regenerative Medicine—is Tissue Engineering The Tissue Engineering Triad Current Commercial Skin Substitutes cellule Tissue engineeringtriads, single cell suspension, growth factors, monolayer cultures and synthetic scaffolds struggle to regenerate complete functional tissues and ar

  15. Slide 15: SkinTE

    SKINIE An Entirely Different Approach to the NEO-generation of Autologous Skin and Patient- Specific Wound Care Acute and Chronic Wounds || Trauma |)Burns || Surgical Reconstruction || Scar Revision SkinTEis intended to be used by physicians and other appropriate nee providers for autologous homolog

  16. Slide 16: SkinTE: Simply Put, Regenerates Skin

    SkinTE || Simply Put || Regenerates Skin SkinTE Applied to Complex Heel Defect || osed Bone, Tendon & Muscle || 12 Weeks of Healing ‘SkinTEis intended to be used by physicians and other appropriate healthcare providets for autologous homologous uses of the skin and integumentary system. Patients who

  17. Slide 17: Press Release: Best Presentation Award

    PRESS RELEASE PolarityTE Awarded Best Presentation at the 2018 American Professional Wound Care Association 17th Annual National Clinical Conference for SkinTE Technology and Clinical Outcomes CLINICAL CONFERENCE ] -smevananan + Repigmentation + Formation of sweat and hair follicles + 2-point discri

  18. Slide 18: SkinTE: Functional Polarization and Hierarchical Organization

    SkinTE™: Functional Polarization and Hierarchical Organization Native Skin Comparative Anatomy O Epidermal, dermal and hypodermal compartments ate Autologous SkinTE™ QA dermal/epidermal junction with rete pegs QO Appendages (hair follicles, glands) and regenerative ae ; = Rag structures OTS Advanced

  19. Slide 19: Native Skin

    Native Skin ee Comparing SkinTE™ to Native Skin. Comparative of analysis of ancillary histology between SkinTE™ (left) and native skin (right). Ancillary stains include: Hematoxylin and Eosin, Trichrome and PeriodicAcid-Schiff. The images and data presented hereare from pre-clinical studies. 19

  20. Slide 20: SkinTE Compared to Commercially Available Skin Substitutes

    SkinTE™ Compared to Commercially Available Skin Substitutes Skin is Much More thana Single Layer of Cells Providinga Barrier - Skinis the Largest Organ In The Human Body And Requires Regeneration Of All Components For Normal Function “[Without the component of the recipients own distinct epithelium

  21. Slide 21: What is SkinTE?

    What is SkinTE™? For the repair, reconstruction & Teplacement of full-thickness skin SkinTE is a human cellular and tissue-based product derived from a patient’s own skin to regenerate full-thickness, functionally-polarized skin with all of its layers (epidermis, dermis and hypodermis) and appendage

  22. Slide 22: SkinTE: A Simple Approach to Complex Problems

    SkinTE™ || A Simple Approach to Complex Problems ares onto ake a smal fulthces sin serplofon te patrrard irre fetayTem the proved pare Se iy PolaritylE 2. Poy manures STE Patient Overview: Middle-aged male who suffered injuries during a motor vehicle collision to both his left and right lower extrem

  23. Slide 23: Sensation and Bio-Impedance

    Sensation and Bio-Impedance P er to monitor progre: on of epithelialization, re |= SkinTE c= Native Skin mm STSG iS z NS NS NS 74 eyo ri rr . i lop a I £ 4 & = g fee on pny ntially imaged Molecular Fingerprinting of the Hair Follicle: SkinTEvs. Native Skin HF Native Skin = Raman Intensity (cps) 1800

  24. Slide 24: Our Goal, Our Cause, Our Belief, Our Priority

    Our GOAL || Our CAUSE || Our BELIEF | Our PRIORITY 1. A Totally DIFFERENT and BETTER Technology 2. The EASY Technology for ALL to use 3. LOWER COST and IMPROVING Health Economics 4, SIMPLE Reimbursement that WORKS for All Parties od

  25. Slide 25: SkinTE: Designed and Developed for ALL

    SkinTE: Designed and Developed for ALL From a small piece of tissue to the regeneration, replacement and/or reconstruction of full-thickness, hair-bearing skin } Product Designed for All SkinTE was specifically designed to reduce barriers to regenerative wound care treatment for patients, providers

  26. Slide 26: SkinTE: Early-Stage Healing in Patients

    SkinTE™ || Early-Stage Healing in Patients SkinTE™ was designed and developedtotreata full spectrum of defects and conditions of the skin ina mannerwhich truly promotes and utilizes the concept of self regeneration : hy early onin the healing process—Where Self Regenerates Selfe > ale en Conditions

  27. Slide 27: Early-Stage Healing in Patients: Where Skin Grafts Fail

    SkinTE™ || Early-Stage Healingin Patients || Where Skin Grafts Fail {_ Infected Subacute Burn Woundsand Exposed Bone Complex and Acute Traumatic Wounds 16 Weeks Following SkinTE 4 Weeks Following SkinTE BSISCEMEDE of Skin Grafts and ScarContractures J Permanent Skin for Large TBSA% Acute Burn Covera

  28. Slide 28: SkinTE: Waging War on Skin Grafts

    SkinTE™ || Waging War on Skin Grafts | Different Cells and Structures Exist at Different Layers within the Skin—Taking Only Some of them Prevents the Regeneration of Full-Thickness Hair-Bearing Skin SKIN GRAFTS - LIMITED DONOR SKIN NATIVE DONOR SKIN IS LIMITED: Full-thickness autograft skin, which i

  29. Slide 29: SkinTE vs. Skin Grafts: Donor Sites DO Matter

    _ SkinTE vs. Skin Grafts—Donor Sites DO Matter Skin Graft Donor Site @ 2 years Following Dermatome } Consider Donor Site(s) Size and Expansion Pain Scar Type of Facility Type of Provider Split-Thickness Skin Grafts

  30. Slide 30: Expansion and Growth on the Patient: Human Bioreactor

    Expansion and Growth onthe Patient || Human Bioreactor SkinTE™ was designed and developed totreata full spectrum of defects and conditions of the skin in a manner which truly promotes and utilizes the conceptof self regeneration early on in the healing process —Where Self Regenerates Self™ Progressi

  31. Slide 31: Native Skin vs SkinTE

    Native Skin SkinTE™ SkinTE Following Replacement of Split-Thickness Skin Graft in Fibrotic Wound Bed Conducting Pinch Test of SkinTE at 6 months Dermascope Punch Biopsy of SkinTE Depicts All Layers of Full-ThicknessSkinand Appendages Rete Pegs Located at Epidermal /Dermal Junction Prevent ShearSkin

  32. Slide 32: SkinTE Biopsy: Correlative Layers of Skin

    SkinTE™ Biopsy - Correlative Layers of Skin ee Patient Punch Biopsy of SkinTE Depicts All Layers of Full-Thickness Skin KIN Rete Pegs Located at Epidermal/Dermal Junction which Prevent Shear Skin Haematoxylin and Eosin Periodic Acid Schiff Trichrome Blue Epidermis Dermis Stratum Corneum Stratum Luci

  33. Slide 33: SkinTE: Coverage of Failed Areas of Skin Grafts

    SkinTE™ - Coverage of Failed Areas of Skin Grafts Acute Scald Burn to torso, genatialia, thighsin a 2-year-old Areas of failed skin graft treated with SkinTE SkinTE - Progression over 1 Month Before } I LANGA SkinTE STSG Contraction

  34. Slide 34: Commercialization Updates for SkinTE

  35. Slide 35: SkinTE: Commercialization and Staged Growth

    SkinTE™- Commercialization and Staged Growth - ee STAGE 1: Product Development Finalization of the SkinTE product development with the goal of the easy product to choose and simple product touse STAGE 2: FDA 361 HCT/P Process Verification(s) FDA regulatory processes for verified registrations and si

  36. Slide 36: Current Addressable Markets

    Current Addressable Markets [ UnitedStatesMarkets _ | ? . . «i ct 2 Burn Wounds Relative Wound Incidence Relative Wound Size Relative Market Size 127 Burn Centers >$3 Billion Addressable Market CD) Surgical Reconstruction & Traumatic Wounds 600 Level L-Ill Trauma Centers >$23 Billion Addressable Mar

  37. Slide 37: Commercialization of the SkinTE Tissue Product

    Commercialization of the SkinTE Tissue Product 2018 I } 01S | 2020 Limited Market Release Deep Product Insight i Market Segmentation Polarity Sales Team Covering Entire US Controlled Logistics Multi-Tier System Approach Following National Medical Conferences KOL Development Targeting Timelines - Ski

  38. Slide 38: Review: Commercialization of the SkinTE Tissue Product

    Review || Commercialization of the SkinTE Tissue Product 2018 | (cee cm 2020 Review ofthe SkinTE Regional Market Release ee I + During the fiscal third quarter (ended July 31, 2018) we transitioned from the Common Site Initiation limited market release (LMR) to the regional market release (RMR). Pro

  39. Slide 39: SkinTE: A Comprehensive Approach to Skin Regeneration

    SkinTE™ || AComprehensive Approach to Skin Regeneration | Approach From ALL Directions | For the repair, reconstruct n ion c of futhicness oh 39

  40. Slide 40: A Totally Different Type of Support

    3S Sipe OSS a ey A Totally Different Product | A iistally Different Type of Support 24-Hour Product Support with PolarityTE RTA The PolarityTE Real-Time Assistant (RTA) application is a HIPAA-compliant product support tool to facilitate communication between PolarityTE and providers.

  41. Slide 41: PolarityTE Real-Time Assistant App

    PolarityTE™ Real-Time Assistant App : . PolarityTE A face-to-face consultation with a aI PolarityTE™ physician 24 hours a day. A New Way to Communicate and Use PolarityTE® Products: The PolarityTE* Real-Time Assistant App for iO: Ws Peer-to-Peer Support Between Medical Professionals andPolarityTE® P

  42. Slide 42: Reimbursement for SkinTE: Keep it Simple

    Reimbursement for SkinTE || Keep it Simple a | =a ee ei | A Simple and Sensible Reimbursement System with Basic Codes ‘orward Cost-Reduction and Improve Health Economics )SKinTE” REIMBURSEMENT GUIDE t, Providerand Payer PM Access to the product sparking a paradigm shift = SkinTE is available for pat

  43. Slide 43: Next Platform Product on the Horizon?

    Next Platform Product on the Horizon? 43

  44. Slide 44: OsteoTE: Expected to Launch in Late 2018

    Os stgoTEM- Expected to Launch in Late 2018 a OsteoTE™ is an autologous - from the patient, for the patient - productintended forbone repair, reconstruction, replacement, supplementation and regeneration, includingin the long bone, craniomaxillofacial, spine, dental, handand foot/ankle markets. a4

  45. Slide 45: OsteoTE: Regeneration of Bone in Critical Defects

    OsteoTE™ — Regeneration of Bone in Critical Defects Defect Native (CT) Ss) Week 8 Bd (CT) S eM i, _ — Surface Pty Comparative Imaging of CLICSAM Substrate in Critical Sized Cranial Defect Model System. (a.) Three dimensional (3-D) micro computed tomography (micro-CT) native cranial bone displaying p

  46. Slide 46: Comparing OsteoTE to Native Bone and Other Products

    Comparing OsteoTE™ to Native Bone and Other Products Belaezee Interfaces Drive Vascularized Osteogenesis OsteoTE. oe ative, BONE a. OsteoTE+ BGM OsteoTE+DGAU° Autologous Bone Plate DBM + BMP2 DBM+BMP2 OsteoTE +DGALLO OsteoTE +BGALO OsteoTE © Auto BonePlate Defect Control Native Bone

  47. Slide 47: OsteoTE: Molecular Fingerprinting of Native Functional Tissues

    OsteoTE™: Molecular Fingerprin ive Functional Tissues | Integrative Angiogenesis and Osteogenesis Correlate this with Functional Outcomesand Tissue Fingerprints Osteogenesis Profile Angiogenesis Profile i Fi a i 60 A i : H 1 3 OsteoTE +86 g 50 OsteoTE +06 |, { Es i : % OsteoTE i z \ Native Bone f 4

  48. Slide 48: OsteoTE Preclinical Completed

    Autologous Bone Graft DBM + BMP2 AHBC Bone Mineral Density OsteoTE Preclinical Completed CME —*—~—~—~7~7>ESSEE=S LongBone | ae —$——$————=—s> 4.

  49. Slide 49: Current Strategic Imperatives & Recent Notable Achievements

    Current Strategic Imperatives & Recent Notable Achievements Accomplished in Preceding 12 months Expectations and Catalysts for Next 12-18 Months _ Corporate Growth > 120 employees with 50% having advanced degrees -_~ Continue With Commercial Roll Out of SkinTE in US, Drive Revenues And + AnExperienc

  50. Slide 50: PolarityTE: YES, WE ARE DIFFERENT

    PolarityTE® || YES—WE ARE DIFFERENT | PolarityTE & Paradoxical Innovation | We Have Been Successful, Growing and Ahead of Schedule A Different Technology, Team, View, Approach and Cause We Know We Are Different and We Take Pridein This We ARE NOT and WILL NOT Bea Single Product Type of Company We Wi

  51. Slide 51: Innovation is NOT Always What is Asked For

    PolarityTE® I Innovation is NOT Always What is Asked For “IF | HAD ASKED PEOPLE WHAT THEY WANTED, THEY WOULD HAVE SAID: FASTER HORSES...”

  52. Slide 52: The PolarityTEAM: Management

    The PolarityTEAM: Management Denver Lough, MD, PhD Edward Swanson, MD Paul Mann CFA, MSE Cameron Hoyler, JD Chief Executive Officer & Chairman Chief Operating Officer Chief Financial Officer EVP Corporate Development & Chief R&D Officer John Hopkins Hospital & School of Highbridge Capital Strategy J

  53. Slide 53: The PolarityTEAM: Board of Directors

    i "0 The PolarityTEAM: Board of Directors Peter Cohen, MBA Director * Former BoardMember of the NYSEand Chairman and CEO of Cowen Inc. + Member of the Board of Directors of Quadrant Biosciences, Inc., and Vice Chairman and Lead Director of the Board of Directors of Scientific Games Corporation. Aerv

  54. Slide 54: The PolarityTEAM: Clinical Advisory Board

  55. Slide 55: PolarityTE Corporate: Thank You

    PolarityTE® Corporate a ha nl Yo u | 0 i | Website: www.PolarityTE.com B _ Email: ParadigmShift@PolarityTE.com a Corporate Inquiries: (800) 378-2694 Your Time re veinom o PolarityTE® Investors Relations eas Rich Haerle MBA, MPH ee VP of Investor Relations IR Inquiries: (385) 237-5786 Email:ir@Polari

PolarityTE — Investor Presentation (October 2018) on 6ix